In the POETYK PsA-2 trial, 54.2% of Sotyktu-treated patients achieved ACR20 at Week 16 vs. 39.4% on placebo. Sotyktu improved PsA disease activity, including clinical signs, extra-articular ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in psoriatic arthritis (PsA), the company has presented detailed data from ...

Bristol-Myers Squibb (NYSE:BMY) on Saturday announced results from a late-stage trial for its psoriasis therapy Sotyktu in psoriatic arthritis, noting that more than 50% of trial participants who ...

New 5-year data on the efficacy and safety of Sotyktu show consistent results for adults with moderate to severe psoriasis. Rates of serious adverse events were similar to other psoriasis treatments.

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials. The Protagonist Therapeutics-partnered IL-23 ...

US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) trial of its drug candidate Sotyktu (deucravacitinib) for plaque ...

Bristol Myers (BMY) Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis. The POETYK PsA-2 ...

Meanwhile, in the ICONIC-ADVANCE studies, icotrokinra was able to outperform Sotyktu on a series of endpoints designed to show superiority to Sotyktu at 16 and 24 weeks. J&J's head of ...

Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...

Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 inhibitor Sotyktu (deucravacitinib) in adults with moderate-to-severe plaque ...

Bristol Myers (BMY) Squibb announced new five-year results from the POETYK PSO long-term extension, LTE, trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis.